GI Innovation and LaNova Medicines have signed an MOU to develop a combination therapy using GI-102 and ADC LM-302 for pancreatic cancer treatment. The collaboration follows promising preclinical results showing excellent anticancer activity in pancreatic cancer models, potentially offering a new treatment option in an area with limited therapeutic choices.